《大行報告》摩通降信達生物(01801.HK)評級至「中性」 目標價升至62元
摩通發表的研究報告指,信達生物(01801.HK)股價今年以來已升約112%,主要受惠多元化產品進展穩健,疫情亦令投資者對高質素醫藥企業胃納增加,而流動性供應亦顯著。
雖然該行相信公司有穩健基礎應付未來數年的發展,但考慮到升勢強勁,難予「增持」評級,並認為股價表現與公司基本面之間的差異有憂慮,故將評級降至「中性」,建議投資者應等更好的入市機會,目標價由38元升至62元以反映近期產品線方面的進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.